Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
- Resource Type
- article
- Authors
- William L. Read; Felicia Williams
- Source
- Case Reports in Oncology, Vol 9, Iss 3, Pp 639-643 (2016)
- Subject
- Alveolar soft part sarcoma
Soft tissue sarcoma
Sunitinib
Pazopanib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
- Language
- English
- ISSN
- 1662-6575
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with a propensity for lung metastases and indolent progression. ASPS is not responsive to chemotherapy, but there are case reports and small series describing benefit from drugs targeting the VEGF pathway. These drugs include sunitinib, cediranib and bevacizumab. There is no established second-line treatment for persons with ASPS progressing through first-line targeted therapy. We report two individuals with metastatic ASPS who obtained disease stabilization from sunitinib lasting over a year. After subsequent progression through sunitinib and second-line bevacizumab, both individuals again had disease response and subsequent stabilization from pazopanib.